Navigation Links
CV Therapeutics' Anti-Ischemic Therapy Ranexa(R) Significantly Reduces Cardiac Chest Pain Symptoms and Recurrent Ischemia in MERLIN-TIMI 36 Patients With Angina
Date:4/1/2008

CHICAGO, April 1, 2008 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc. (Nasdaq: CVTX) today announced new data presented at the 57th Annual Scientific Sessions of the American College of Cardiology shows that Ranexa(R) (ranolazine extended release tablets) significantly reduced the risk of recurrent ischemia (p=0.002), worsening angina (p=0.048) and intensification of antianginal therapy (p=0.009) in angina patients (n=3,565) in the MERLIN- TIMI 36 study.

Additionally, Ranexa significantly improved all measures of exercise performance compared to placebo, including reductions in the time to onset of angina (p=0.002) and time to the onset of 1 mm ST segment depression (p=0.002), a signal of ischemia, in these MERLIN-TIMI 36 angina patients.

"MERLIN-TIMI 36 is the largest study of ranolazine in patients with established coronary artery disease," said David Morrow, M.D., MPH, of Brigham & Women's Hospital at Harvard Medical School and lead investigator of the MERLIN-TIMI 36 study. "This new subgroup analysis shows consistent safety and efficacy across a broader group of angina patients than those studied previously and reaffirms ranolazine as an option for treating chronic angina."

Study Design

MERLIN-TIMI 36 (Metabolic Efficiency with Ranolazine for Less Ischemia in Non-ST Elevation Acute Coronary Syndromes) was a multi-national, double-blind, randomized, placebo-controlled, parallel-group clinical trial designed to evaluate the efficacy and safety of Ranexa during acute and long-term treatment in 6,560 patients (3,279 received ranolazine, 3,281 received placebo) with non-ST elevation ACS treated with standard therapy.

Previously published data from the MERLIN-TIMI 36 study has shown that Ranexa was safe i
'/>"/>

SOURCE CV Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

2

GOOD

Page: 1 2 3

Related medicine technology :

1. Michael J. Fox Foundation Commits up to $10 Million for Pre-Clinical Drug Development Under Therapeutics Development Initiative
2. Synvista Therapeutics Presents New Preclinical Data Demonstrating the Value of Haptoglobin Genotype Testing In Diabetes at ACC Scientific Sessions
3. Cell Therapeutics, Inc. (CTI) Announces Enrollment Complete in Phase III EXTEND (PIX301) Clinical Trial of Pixantrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL
4. Dynamis Therapeutics, Inc. Discovers RAGE Inhibitor
5. Lilly and Transition Therapeutics Announce Licensing and Collaboration Agreement
6. Amicus Therapeutics Presents Data from Clinical Ex Vivo Response Study and Phase 1 Studies of AT2220
7. Ception Therapeutics Initiates Phase II/III Clinical Trial for Its Lead Product Reslizumab in Eosinophilic Esophagitis (EE) in Children
8. Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for XYOTAX(TM)
9. InteKrin Therapeutics Announces Initiation of Phase 2b Study in Type 2 Diabetes with INT131
10. Oncology Drug Development Update - Molecular Profiling Redefines the Nature of Malignancy and Increases the Adoption of Targeted Therapeutics
11. TorreyPines Therapeutics Announces Strategic Plan with Focus on Clinical Development Activities to Maximize Value of Versatile Lead Compounds

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/29/2009)...swire/ -- Stimulated by the ten years of Synapse&#...ystems USA announced today, at the Radiological So...formation of its Medical Informatics Division . ... will integrate all functions associated with the ...orm for future growth. ,, Several organizationa...
(Date:11/28/2009)...ewswire/ -- Siemens Healthcare redefines producti...al imaging matrix) technology and with its new Dot...nologies are introduced in the new MAGNETOM ®...3T scanners at the 95th Scientific Assembly and An...America (RSNA) from November 29 to December 3 at M...
(Date:11/27/2009)...27 ACUO TECHNOLOGIES, developers o...re, data migration tools and services, is pleased ...emark Office has approved a patent application for...Network." Acuo Technologies is pleased to add the ...rty. In general, the granted patent application br...
Breaking Medicine Technology:FUJIFILM Establishes Medical Informatics Organization 2FUJIFILM Establishes Medical Informatics Organization 3Siemens Introduces Its New Power Couple at RSNA 2009 2Siemens Introduces Its New Power Couple at RSNA 2009 3Siemens Introduces Its New Power Couple at RSNA 2009 4Siemens Introduces Its New Power Couple at RSNA 2009 5Siemens Introduces Its New Power Couple at RSNA 2009 6Siemens Introduces Its New Power Couple at RSNA 2009 7Acuo Technologies Announces Patent for Asset Communication Format Within a Computer Network 2Sediment yields climate record for past half million years 8845 1Sediment yields climate record for past half million years 8845 2A Substitute for Those Who Cant Take Statins 3F 48961 1A Substitute for Those Who Cant Take Statins 3F 48961 2A Substitute for Those Who Cant Take Statins 3F 48961 3Top CEOs Declare Americas Manufacturing Sector Requires Pro Industry Policies Capital Management and Innovation to Maintain Economic Leadership 12632 1Top CEOs Declare Americas Manufacturing Sector Requires Pro Industry Policies Capital Management and Innovation to Maintain Economic Leadership 12632 2Top CEOs Declare Americas Manufacturing Sector Requires Pro Industry Policies Capital Management and Innovation to Maintain Economic Leadership 12632 3
...RE)--Jun 6, 2007 - Gilead,Sciences, Inc. (Nasdaq:G...linical trial evaluating the company,s once-daily,...e or tenofovir,DF) 300 mg as a potential treatment...t its primary efficacy endpoint. The study shows,t...aily antiviral,drug Hepsera(R) (adefovir dipivoxil...
...ux - , Waltham, Mass., June 7, 2007 – Dynoge...of its randomized, double-blind,placebo-controlle...flux disease (GERD). The study was designed to de...nt for nocturnal GERD,(NGERD). The 0.5 mg dose o...acebo on the primary endpoint of reduction in,the ...
Other Medicine Technology:Phase III Study Evaluating Gilead's Viread for the Treatment of,Chronic Hepatitis B Virus Meets Primary Endpoint 2Phase III Study Evaluating Gilead's Viread for the Treatment of,Chronic Hepatitis B Virus Meets Primary Endpoint 3Phase III Study Evaluating Gilead's Viread for the Treatment of,Chronic Hepatitis B Virus Meets Primary Endpoint 4Phase III Study Evaluating Gilead's Viread for the Treatment of,Chronic Hepatitis B Virus Meets Primary Endpoint 5Phase III Study Evaluating Gilead's Viread for the Treatment of,Chronic Hepatitis B Virus Meets Primary Endpoint 6Phase III Study Evaluating Gilead's Viread for the Treatment of,Chronic Hepatitis B Virus Meets Primary Endpoint 7Dynogen's DDP733 Reduces Reflux in Phase 1b GERD Study 2Dynogen's DDP733 Reduces Reflux in Phase 1b GERD Study 3
(Date:11/29/2009)...ral Dentistry (AGD) announces that Aria Irvani, DD...ard during the AGD,s commencement celebration that...in dental education.,To accomplish this, Dr. Irva...ntal education in the 16 disciplines of dentistry,...and techniques. , (PRWEB)...
(Date:11/29/2009)...rs-in-training how to do ultrasound-guided procedu...thout compromising patient care and safety, accord...he study shows that this simulation-based training...residents, knowledge, dexterity and confidence for...ded procedures, including breast biopsies, liver b...
(Date:11/29/2009)...form between brain cells almost immediately as ani...hed this week in Nature . Led by researchers at t... involved detailed observations of the rewiring pr...learning. , The researchers studied mice as they...d. They observed rapid growth of structures that f...
(Date:11/29/2009)...swire/ -- Acuo Technologies, developers of high-pe...migration tools and services, today announced a ne...age sharing across the networks of hospitals, clin... is based on the versatile Acuo Technologies DICOM...nables secure access from various PACS to medical ...
(Date:11/29/2009)...eads to more self-defensive finger pointing, study...ws) -- The blame game is a contagious one, a new s..., Researchers found that when people see someone ...unfair accusation, they,re much more likely to eng...ers protecting their egos, we become defensive, to...
Breaking Medicine News(10 mins):Health News:Orange County Dentist Honored by The Academy of General Dentistry 2Health News:Simulated training for ultrasound-guided procedures improves safety without risk to patients 2Health News:Study shows new brain connections form rapidly during motor learning 2Health News:Study shows new brain connections form rapidly during motor learning 3Health News:Acuo Technologies Announces a New Offering That Enables Sharing of Imaging Studies Securely and Affordably 2Health News:When Accusations Start to Fly, They Multiply 2
...rican Physical Therapy Association (APTA) is urgin...reatment by a physical therapist, in light of a ne...of American adults and nearly 12 percent of childr...e released Dec. 11 by the National Institutes of H...
...of Denver (DU) Associate Professor Rene Botta sugg...raduate students to wash their hands more frequent... 2007, researchers posted messages in the bathroom...ined vivid graphics and photos. The messages resul...
...DS joins PEPFAR, Nike Foundation, Coca-Cola Africa...ree Generation , , NAIROBI, Kenya, Dec. 15 A...d at disadvantaged young people in Nairobi will re... Those efforts, in turn, are intended to help you...
... Food,and Drug Administration (FDA) approved Abbot... capsules for use along with diet to help lower tr...cholesterol in patients with lipid,problems. TRIL...nation of a fibrate with a statin to further impro...
...paign for Tobacco-Free Kids , , WASHINGTON, D... major victory for consumers and public health by ...ion laws to sue Philip Morris and other tobacco co...n important step toward holding cigarette manufact...
...to Controlling Costs, Improving Quality as Health ...ice , , WASHINGTON, Dec. 15 House Ways and M... , D-Calif., and Liz Fowler , senior counsel to S...on a conference call with reporters on Wednesday t...
Other Medicine News:Health News:Physical therapy offers evidence-based solution to musculoskeletal pain 2Health News:University of Denver uses 'gross' messaging to increases handwashing, fight Norovirus 2Health News:Rotary Action Group Helps Launch Major Public-Private HIV Prevention Initiative in Kenya 2Health News:Rotary Action Group Helps Launch Major Public-Private HIV Prevention Initiative in Kenya 3Health News:Abbott Receives FDA Approval for TRILIPIX(TM) (fenofibric acid), First and Only Fibrate Indicated for Use in Combination With a Statin for Cholesterol Management 2Health News:Abbott Receives FDA Approval for TRILIPIX(TM) (fenofibric acid), First and Only Fibrate Indicated for Use in Combination With a Statin for Cholesterol Management 3Health News:Abbott Receives FDA Approval for TRILIPIX(TM) (fenofibric acid), First and Only Fibrate Indicated for Use in Combination With a Statin for Cholesterol Management 4Health News:U.S. Supreme Court Ruling Allowing Light Cigarette Lawsuits Is Victory for Consumers and Health 2Health News:U.S. Supreme Court Ruling Allowing Light Cigarette Lawsuits Is Victory for Consumers and Health 3
...vel of engineering and innovative design, the Burt...n, unparalleled quality and masterful workmanship....almic industry a truly innovative concept, but to ...quality construction and stringent testing, we dev...
...mporary Soft Touch control panel with 3 charging w...k, Colonial Blue and Cinnamon. Spring balanced ref...teel construction for lifelong quality. Sealed hyd...wn chair movement. Chair back reclines manually to...
...ar warranty Set one of two memory positions to aut...e touch auto return button, Durable upholstery,...id-State push button control panel with three rech...lectro-Magnetic counter-balanced slit lamp arm for...
...ol Ophthalmics™ Balanced Salt Solution (Ster...late, physiologic solution which is isotonic to oc... normal cellular metabolic functions. Each 1.0 mL ...SP .48 mg, Magnesium Chloride Hexahydrate (MgCl2 ...
Medicine Products: